Please login to the form below
insulin glargine
This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Latest news
-
Dupixent bounce-back helps stem diabetes declines at Sanofi
Overall sales at the French pharma group fell almost 6% to 8.3bn ($bn), pegged back by unfavourable exchange rates but also a further 21% drop for Lantus (insulin glargine) due
-
Sanofi poaches Peugeot's finance head
The group saw sales from its diabetes blockbuster Lantus (insulin glargine) plummet 18% to 911m (1.1bn) in the first quarter, quite a difference from the drug’s peak in 2014,
-
FDA starts review of Sanofi’s oral type 1 diabetes drug
Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine
-
Sanofi’s latecomer PD-1 gets date for FDA verdict
blockbuster Lantus (insulin glargine) and a poor start for dengue vaccine Dengvaxia.
-
Sanofi warns of difficult few months as diabetes sales slump
As in earlier quarters, the main damage has come from diabetes blockbuster Lantus (insulin glargine), which saw sales decline 18% to 911m ($1.1bn) in the first quarter having reached a
More from news
Approximately 23 fully matching, plus 110 partially matching documents found.
Latest Intelligence
-
Mylan sees the UK paving the way for an insulin game changer
As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
-
Going the distance
In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
-
Pharma deals during February 2013
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Sanofi promotes diabetes expert Paul Chew to chief medical officer
position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Account Manager
-
Negotiable
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Associate Scientific Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Sudler London - Account Director
-
Competitive
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Medical Writers Required - Hertfordshire
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Sudler London - Senior Medical Writer
-
Competitive
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
Subscribe to our email news alerts
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Innovate UK supports AI drug discovery project worth £1m
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Superhuman editor wins promotion at Porterhouse Medical
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
PMHub
EY Life Sciences
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
